Analyst Price Target is $2.50
▲ +226.75% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for VolitionRx in the last 3 months. The average price target is $2.50, with a high forecast of $2.50 and a low forecast of $2.50. The average price target represents a 226.75% upside from the last price of $0.77.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in VolitionRx. This Buy consensus rating has held steady for over two years.
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.
Read More